Most physician prescribers were satisfied with the FDA's controversial risk evaluation and mitigation strategy (REMS) program for clozapine, survey data showed. Among 196 doctors who prescribed ...

For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...

Following the advice of a nearly unanimous joint FDA advisory committee, the agency decided that clozapine's REMS program is no longer necessary to ensure that the benefits of the drug outweigh ...

As reported by Medscape Medical News, panelists urged the agency to end the REMS requirements. “The FDA’s decision to end the clozapine REMS is a crucial step toward improving access to this ...

The FDA still recommends prescribers monitor patients’ ANC levels according to the prescribing information. The Food and Drug Administration (FDA) has removed the risk evaluation and mitigation ...

One in 3 people with schizophrenia don’t respond to antipsychotics — but previous blood test requirements made clozapine difficult to access. The FDA removed a requirement for patients to ...

Clozapine, which was approved in 1989 ... imposed a regimen known as risk evaluation and mitigation strategies, or REMS, that required patients to submit to weekly, biweekly and monthly blood ...

Source: Bethany Yeiser I have taken clozapine successfully for 17 years. One of my biggest fears in life is reduced access to this life-saving medication. Different people need different ...

The FDA has eliminated the need for pharmacists to verify a patient's white blood cell count before dispensing the antipsychotic medication clozapine.

Christine is also registered with the Clozapine REMS program. Outside of work, Christine enjoys being an active member of church, as well as singing in the choir and playing piano, cello ...